Lmr Partners LLP Cassava Sciences Inc Put Options Transaction History

Lmr Partners LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 07, 2024	BUY	$9.57 - $35.08 $2.03 Million - $7.46 Million	212,600 Added 107.16%	411,000 $12.1 Million
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $34,580 - $73,108	2,800 Added 1.43%	198,400 $2.45 Million
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $2.95 Million - $4.23 Million	-160,000 Reduced 44.99%	195,600 $3.97 Million
Q4 2023 Feb 14, 2024	BUY	$12.64 - $30.11 $3.76 Million - $8.96 Million	297,600 Added 513.1%	355,600 $8 Million
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $472,576 - $719,088	28,400 Added 95.95%	58,000 $965,000
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $639,064 - $825,248	29,600 New	29,600 $725,000
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $17.2 Million - $38.5 Million	-1,001,500 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $9.91 Million - $16.1 Million	-304,000 Reduced 23.29%	1,001,500 $37.2 Million
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $48 Million - $119 Million	1,305,500 New	1,305,500 $57.1 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $160M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.